Pancreatic cancer remains one of the most challenging cancers to treat, partly because of the limited number of effective targeted therapies available. Rasonque (daraxonrasib) brings attention to one of the most important pathways driving tumour growth: RAS.
Taken as a once-daily oral therapy, Rasonque targets multiple forms of the RAS protein and is approved for adults with metastatic pancreatic adenocarcinoma in specific treatment settings.
Its approval introduces a new targeted approach for a disease with significant unmet need. For clinical trial and first-to-file teams, Rasonque is likely to be a molecule worth watching as its role in pancreatic cancer treatment develops.
